Table 3.
Univariable cox regression analysis for possible predictors of all-cause mortality, cardiovascular events and cardiovascular mortality
| All-cause mortality | Cardiovascular events | Cardiovascular mortality | |||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95.0% CI | p | HR | 95.0% CI | p | HR | 95%CI | p | |
| Age | 1.054 | 1.032–1.076 | < 0.001 | 1.037 | 1.017–1.057 | < 0.001 | 1.036 | 1.006–1.066 | 0.017 |
| Sex | 0.792 | 0.445–1.412 | 0.430 | 0.546 | 0.300–0.914 | 0.048 | 0.657 | 0.268–1.612 | 0.359 |
| History of diabetes | 2.547 | 1.451–4.470 | 0.001 | 2.684 | 1.556–4.629 | < 0.001 | 2.650 | 1.142–6.151 | 0.023 |
| BMI (kg/m2) | 1.135 | 1.083–1.217 | < 0.001 | 1.119 | 1.032–1.214 | 0.006 | 1.069 | 0.945–1.209 | 0.287 |
| MAP | 0.998 | 0.967–1.030 | 0.904 | 1.021 | 0.991–1.052 | 0.181 | 1.022 | 0.976–1.071 | 0.353 |
| Use of statins | 1.263 | 0.553–2.882 | 0.579 | 1.639 | 0.875–3.069 | 0.123 | 1.978 | 0.773–5.509 | 0.155 |
| Use of RAAS antagonists | 0.577 | 0.317–1.049 | 0.072 | 0.575 | 0.323–1.024 | 0.060 | 0.389 | 0.143–1.055 | 0.064 |
| Use of anti-hypertensive drugs | 0.683 | 0.271–1.723 | 0.419 | 0.895 | 0.322–2.489 | 0.832 | 2.451 | 0.103–3.256 | 0.404 |
| LVMI (g/m2) | 1.010 | 1.001–1.020 | 0.027 | 1.017 | 1.008–1.025 | < 0.001 | 1.012 | 0.999–1.026 | 0.073 |
| LVMI -progression | 1.417 | 1.049–1.915 | 0.023 | 1.359 | 1.015–1.820 | 0.039 | 1.475 | 0.935–2.326 | 0.095 |
| Hemoglobin (g/L) | 0.990 | 0.970–1.010 | 0.319 | 0.996 | 0.977–1.016 | 0.717 | 1.005 | 0.974–1.038 | 0.735 |
| Albumin (g/L) | 0.954 | 0.890–1.023 | 0.187 | 1.011 | 0.940–1.088 | 0.761 | 1.046 | 0.938–1.165 | 0.418 |
| CHO (mmol/L) | 1.028 | 0.748–1.412 | 0.866 | 0.971 | 0.705–1.337 | 0.857 | 1.022 | 0.637–1.640 | 0.928 |
| LDL (mmol/L) | 1.239 | 0.820–1.874 | 0.309 | 1.187 | 0.790–1.783 | 0.408 | 1.243 | 0.676–2.286 | 0.484 |
| TG (mmol/L) | 0.883 | 0.659–1.182 | 0.403 | 0.977 | 0.759–1.257 | 0.856 | 0.531 | 0.273–1.036 | 0.063 |
| HDL (mmol/L) | 1.157 | 0.438–3.057 | 0.768 | 0.354 | 0.115–1.091 | 0.071 | 1.867 | 0.481–7.244 | 0.367 |
| ApoA (g/L) | 1.262 | 1.108–1.437 | < 0.001 | 1.127 | 1.103–1.463 | 0.001 | 1.315 | 1.140–1.517 | < 0.001 |
| ApoB (g/L) | 2.495 | 0.411–3.309 | 0.772 | 1.953 | 0.293–12.992 | 0.489 | 0.682 | 0.109–29.868 | 0.682 |
| hsCRP (mg/L) | 1.001 | 0.967–1.037 | 0.936 | 1.018 | 0.992–1.044 | 0.178 | 1.004 | 0.955–1.055 | 0.884 |
| nPCR (g/kg/24 h) | 0.040 | 0.006–0.256 | 0.001 | 0.107 | 0.017–0.653 | 0.016 | 0.222 | 0.016–3.123 | 0.265 |
| Urinary output(L/24 h) | 0.542 | 0.309–0.952 | 0.033 | 0.856 | 0.499–1.467 | 0.571 | 0.771 | 0.325–1.830 | 0.556 |
| Total Ccr (L/week) | 0.997 | 0.985–1.009 | 0.646 | 0.998 | 0.987–1.010 | 0.786 | 1.001 | 0.984–1.019 | 0.880 |
| Residual renal Ccr (L/week) | 0.997 | 0.986–1.008 | 0.575 | 0.998 | 0.987–1.008 | 0.650 | 0.999 | 0.989–1.009 | 0.872 |
| Total Kt/V | 1.075 | 0.931–1.241 | 0.326 | 1.081 | 0.931–1.254 | 0.305 | 1.148 | 0.997–1.323 | 0.055 |
| Residual renal Kt/V | 0.814 | 0.438–1.511 | 0.514 | 0.834 | 0.460–1.511 | 0.549 | 0.995 | 0.403–2.459 | 0.992 |
| Proportion of 1.5%-glucose dialysate(%) | 1.452 | 0.263–8.014 | 0.669 | 1.057 | 0.172–6.479 | 0.952 | 2.080 | 0.178–24.236 | 0.559 |
| Volume of dialysate (per1000mL/24 h) | 1.319 | 1.096–1.586 | 0.003 | 1.294 | 1.075–1.557 | 0.006 | 1.193 | 0.898–1.583 | 0.223 |